Jazz agrees to pay $145 million to settle Xyrem indirect purchaser class claims
Jazz Pharmaceuticals Ireland Limited agreed on April 7, 2025 to a preliminary class settlement with indirect Xyrem purchasers, paying $145 million in a lump sum from cash on hand. The company expects a pre-tax charge of about $145 million in the first quarter of 2025, and the deal remains subject to court approval. Shareholders face a known cash cost and a charge, and the company warns that further settlements with other plaintiffs may add significant charges.
Key points
- Lump-sum payment of $145 million, funded with cash on hand
- Expected pre-tax charge of approximately $145 million in the first quarter of 2025
- Settlement requires Court approval and can be rescinded if a specified percentage of potential class members opt out
- Company may enter additional settlements with remaining plaintiffs, which could be significant; the company denies wrongdoing
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 08, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.